Clinical Trial: NCT04684563
huCART19-IL18 in CD19+ Cancers
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | University of Pennsylvania |
| Information Provided By: | University of Pennsylvania |
| Last Update Posted: | 2025-11-10 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.
Official Title
Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Cancers
Conditions
Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Intervention / Treatment
- Biological: huCART19-IL18
Other Study ID Numbers
- 15420; IRB# 844955
Start Date (Actual)
2021-05-06
Primary Completion Date (Estimated)
2036-05
Study Completion Date (Estimated)
2036-05
Enrollment (Estimated)
72
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | University of Pennsylvania |
| Information Provided By: | University of Pennsylvania |
| Last Update Posted: | 2025-11-10 |
Study Overview
Brief Summary
The purpose of this study is to evaluate the safety and feasibility of huCART19-IL18 cells in patients with relapsed or refractory CD19+ cancers.
Official Title
Phase I Trial of huCART19-IL18 Cells in Patients With Relapsed or Refractory CD19+ Cancers
Conditions
Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Intervention / Treatment
- Biological: huCART19-IL18
Other Study ID Numbers
- 15420; IRB# 844955
Start Date (Actual)
2021-05-06
Primary Completion Date (Estimated)
2036-05
Study Completion Date (Estimated)
2036-05
Enrollment (Estimated)
72
Study Type
Interventional
Phase
Phase 1